Current treatment algorithm: diffuse large B cell lymphoma - PubMed
3 days ago
- #CAR T-cell therapy
- #lymphoma treatment
- #DLBCL
- Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive B-cell malignancy.
- Initial treatment involves anthracycline-based chemotherapy combined with rituximab, aiming for durable long-term survival in two-thirds of patients.
- Treatment is tailored based on disease stage, prognostic features, and molecular subclassification.
- Polatuzumab vedotin is added for the activated B-cell subtype; more intense therapy is used for Myc and BCL-2 rearrangements.
- About one-third of patients relapse, with CAR T-cell therapy recommended for early relapses or resistance.
- Late relapses may receive salvage chemotherapy followed by autologous stem cell transplant.
- Palliative options like bispecific antibodies or antibody-drug conjugates are used for ineligible or post-CAR T-cell progression cases.
- Research is ongoing to integrate cellular and bispecific therapies into front-line treatment to improve outcomes.